Tasly Pharmaceutical Group Co Ltd (600535) - Net Assets
Based on the latest financial reports, Tasly Pharmaceutical Group Co Ltd (600535) has net assets worth CN¥12.55 Billion CNY (≈ $1.84 Billion USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥15.34 Billion ≈ $2.24 Billion USD) and total liabilities (CN¥2.79 Billion ≈ $408.56 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 600535 asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥12.55 Billion |
| % of Total Assets | 81.8% |
| Annual Growth Rate | 19.04% |
| 5-Year Change | -5.75% |
| 10-Year Change | 52.9% |
| Growth Volatility | 58.01 |
Tasly Pharmaceutical Group Co Ltd - Net Assets Trend (1999–2025)
This chart illustrates how Tasly Pharmaceutical Group Co Ltd's net assets have evolved over time, based on quarterly financial data. Also explore 600535 current and non-current assets for the complete picture of this company's asset base.
Annual Net Assets for Tasly Pharmaceutical Group Co Ltd (1999–2025)
The table below shows the annual net assets of Tasly Pharmaceutical Group Co Ltd from 1999 to 2025. For live valuation and market cap data, see Tasly Pharmaceutical Group Co Ltd (600535) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥12.55 Billion ≈ $1.84 Billion |
+3.60% |
| 2024-12-31 | CN¥12.11 Billion ≈ $1.77 Billion |
-4.56% |
| 2023-12-31 | CN¥12.69 Billion ≈ $1.86 Billion |
+0.47% |
| 2022-12-31 | CN¥12.63 Billion ≈ $1.85 Billion |
-5.13% |
| 2021-12-31 | CN¥13.31 Billion ≈ $1.95 Billion |
+7.51% |
| 2020-12-31 | CN¥12.38 Billion ≈ $1.81 Billion |
+4.40% |
| 2019-12-31 | CN¥11.86 Billion ≈ $1.74 Billion |
+5.84% |
| 2018-12-31 | CN¥11.21 Billion ≈ $1.64 Billion |
+24.89% |
| 2017-12-31 | CN¥8.97 Billion ≈ $1.31 Billion |
+9.36% |
| 2016-12-31 | CN¥8.21 Billion ≈ $1.20 Billion |
+6.48% |
| 2015-12-31 | CN¥7.71 Billion ≈ $1.13 Billion |
+52.06% |
| 2014-12-31 | CN¥5.07 Billion ≈ $741.67 Million |
+22.32% |
| 2013-12-31 | CN¥4.14 Billion ≈ $606.32 Million |
-1.50% |
| 2012-12-31 | CN¥4.21 Billion ≈ $615.55 Million |
+11.40% |
| 2011-12-31 | CN¥3.78 Billion ≈ $552.55 Million |
+10.25% |
| 2010-12-31 | CN¥3.42 Billion ≈ $501.18 Million |
+57.75% |
| 2009-12-31 | CN¥2.17 Billion ≈ $317.70 Million |
+3.74% |
| 2008-12-31 | CN¥2.09 Billion ≈ $306.26 Million |
+5.98% |
| 2007-12-31 | CN¥1.97 Billion ≈ $288.96 Million |
+14.81% |
| 2006-12-31 | CN¥1.72 Billion ≈ $251.70 Million |
+9.91% |
| 2005-12-31 | CN¥1.56 Billion ≈ $229.00 Million |
+13.84% |
| 2004-12-31 | CN¥1.37 Billion ≈ $201.15 Million |
+14.41% |
| 2003-12-31 | CN¥1.20 Billion ≈ $175.82 Million |
+20.51% |
| 2002-12-31 | CN¥997.00 Million ≈ $145.89 Million |
+303.32% |
| 2001-12-31 | CN¥247.20 Million ≈ $36.17 Million |
+58.13% |
| 2000-12-31 | CN¥156.32 Million ≈ $22.87 Million |
+15.75% |
| 1999-12-31 | CN¥135.05 Million ≈ $19.76 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Tasly Pharmaceutical Group Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 865192782180.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥8.65 Billion | 69.71% |
| Common Stock | CN¥1.49 Billion | 12.04% |
| Other Comprehensive Income | CN¥1.88 Billion | 15.16% |
| Other Components | CN¥383.01 Million | 3.09% |
| Total Equity | CN¥12.40 Billion | 100.00% |
Tasly Pharmaceutical Group Co Ltd Competitors by Market Cap
The table below lists competitors of Tasly Pharmaceutical Group Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Aspen Pharmacare Holdings Ltd
JSE:APN
|
$3.31 Billion |
|
Star Health and Allied Insurance Company Limited
NSE:STARHEALTH
|
$3.31 Billion |
|
Bread Financial Holdings, Inc.
NYSE:BFH
|
$3.31 Billion |
|
TELEPERFORMANCE SE ADR
F:RCF0
|
$3.31 Billion |
|
Shihlin Electric & Engineering Corp
TW:1503
|
$3.31 Billion |
|
Shanghai M&G Stationery Inc
SHG:603899
|
$3.31 Billion |
|
International Game Technology PLC
NYSE:IGT
|
$3.31 Billion |
|
PVH Corp
NYSE:PVH
|
$3.31 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Tasly Pharmaceutical Group Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 11,903,329,000 to 12,404,228,392, a change of 500,899,392 (4.2%).
- Net income of 1,105,403,000 contributed positively to equity growth.
- Dividend payments of 612,519,502 reduced retained earnings.
- Other comprehensive income increased equity by 4,291,967.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥1.11 Billion | +8.91% |
| Dividends Paid | CN¥612.52 Million | -4.94% |
| Other Comprehensive Income | CN¥4.29 Million | +0.03% |
| Other Changes | CN¥3.72 Million | +0.03% |
| Total Change | CN¥- | 4.21% |
Book Value vs Market Value Analysis
This analysis compares Tasly Pharmaceutical Group Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.82x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 145.97x to 1.82x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1999-12-31 | CN¥0.10 | CN¥15.13 | x |
| 2000-12-31 | CN¥0.12 | CN¥15.13 | x |
| 2001-12-31 | CN¥0.19 | CN¥15.13 | x |
| 2002-12-31 | CN¥0.76 | CN¥15.13 | x |
| 2003-12-31 | CN¥0.87 | CN¥15.13 | x |
| 2004-12-31 | CN¥0.94 | CN¥15.13 | x |
| 2005-12-31 | CN¥1.03 | CN¥15.13 | x |
| 2006-12-31 | CN¥1.13 | CN¥15.13 | x |
| 2007-12-31 | CN¥1.33 | CN¥15.13 | x |
| 2008-12-31 | CN¥1.39 | CN¥15.13 | x |
| 2009-12-31 | CN¥1.49 | CN¥15.13 | x |
| 2010-12-31 | CN¥2.41 | CN¥15.13 | x |
| 2011-12-31 | CN¥2.49 | CN¥15.13 | x |
| 2012-12-31 | CN¥2.76 | CN¥15.13 | x |
| 2013-12-31 | CN¥2.64 | CN¥15.13 | x |
| 2014-12-31 | CN¥3.33 | CN¥15.13 | x |
| 2015-12-31 | CN¥4.98 | CN¥15.13 | x |
| 2016-12-31 | CN¥5.27 | CN¥15.13 | x |
| 2017-12-31 | CN¥5.72 | CN¥15.13 | x |
| 2018-12-31 | CN¥6.95 | CN¥15.13 | x |
| 2019-12-31 | CN¥7.34 | CN¥15.13 | x |
| 2020-12-31 | CN¥7.98 | CN¥15.13 | x |
| 2021-12-31 | CN¥8.64 | CN¥15.13 | x |
| 2022-12-31 | CN¥8.45 | CN¥15.13 | x |
| 2023-12-31 | CN¥8.31 | CN¥15.13 | x |
| 2024-12-31 | CN¥7.97 | CN¥15.13 | x |
| 2025-12-31 | CN¥8.30 | CN¥15.13 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Tasly Pharmaceutical Group Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 8.91%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 13.42%
- • Asset Turnover: 0.54x
- • Equity Multiplier: 1.24x
- Recent ROE (8.91%) is below the historical average (17.84%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1999 | 44.47% | 23.25% | 0.72x | 2.65x | CN¥45.60 Million |
| 2000 | 53.00% | 20.31% | 0.93x | 2.80x | CN¥64.53 Million |
| 2001 | 43.08% | 15.03% | 1.15x | 2.49x | CN¥78.99 Million |
| 2002 | 12.11% | 12.67% | 0.74x | 1.29x | CN¥20.56 Million |
| 2003 | 12.67% | 13.37% | 0.59x | 1.60x | CN¥29.78 Million |
| 2004 | 14.27% | 13.16% | 0.59x | 1.83x | CN¥51.25 Million |
| 2005 | 14.79% | 13.20% | 0.53x | 2.11x | CN¥62.68 Million |
| 2006 | 14.56% | 8.65% | 0.74x | 2.27x | CN¥65.44 Million |
| 2007 | 9.78% | 6.31% | 0.91x | 1.70x | CN¥-4.09 Million |
| 2008 | 13.38% | 7.45% | 1.00x | 1.80x | CN¥64.70 Million |
| 2009 | 15.58% | 7.93% | 0.99x | 1.98x | CN¥113.37 Million |
| 2010 | 13.62% | 9.68% | 0.85x | 1.65x | CN¥119.64 Million |
| 2011 | 16.95% | 9.30% | 0.99x | 1.84x | CN¥250.42 Million |
| 2012 | 21.19% | 9.10% | 1.25x | 1.87x | CN¥449.02 Million |
| 2013 | 28.65% | 9.88% | 1.09x | 2.66x | CN¥714.80 Million |
| 2014 | 28.28% | 10.88% | 0.97x | 2.67x | CN¥884.48 Million |
| 2015 | 19.79% | 11.18% | 0.86x | 2.06x | CN¥731.60 Million |
| 2016 | 14.77% | 8.44% | 0.81x | 2.15x | CN¥380.04 Million |
| 2017 | 15.91% | 8.55% | 0.75x | 2.49x | CN¥511.09 Million |
| 2018 | 14.67% | 8.59% | 0.71x | 2.39x | CN¥491.80 Million |
| 2019 | 9.00% | 5.27% | 0.79x | 2.16x | CN¥-111.61 Million |
| 2020 | 9.40% | 8.29% | 0.82x | 1.38x | CN¥-71.36 Million |
| 2021 | 18.17% | 29.66% | 0.48x | 1.27x | CN¥1.06 Billion |
| 2022 | -2.13% | -3.06% | 0.53x | 1.32x | CN¥-1.50 Billion |
| 2023 | 8.66% | 12.35% | 0.52x | 1.35x | CN¥-165.77 Million |
| 2024 | 8.03% | 11.24% | 0.57x | 1.26x | CN¥-234.75 Million |
| 2025 | 8.91% | 13.42% | 0.54x | 1.24x | CN¥-135.02 Million |
Industry Comparison
This section compares Tasly Pharmaceutical Group Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $1,724,724,027
- Average return on equity (ROE) among peers: 8.55%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Tasly Pharmaceutical Group Co Ltd (600535) | CN¥12.55 Billion | 44.47% | 0.22x | $3.31 Billion |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $780.79 Million | 3.11% | 2.56x | $1.22 Billion |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $1.05 Billion | 2.59% | 0.88x | $438.59 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $10.33 Billion | 15.07% | 0.27x | $5.18 Billion |
| Livzon Pharmaceutical Group Inc (000513) | $623.47 Million | 16.22% | 0.40x | $2.81 Billion |
| Wedge Industrial Co Ltd (000534) | $654.70 Million | 1.92% | 0.87x | $2.95 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $473.92 Million | 15.85% | 0.78x | $13.85 Billion |
| Hainan Haiyao Co Ltd (000566) | $275.57 Million | 17.28% | 1.12x | $949.23 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $702.49 Million | 2.58% | 0.66x | $391.07 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $999.14 Million | 3.56% | 1.59x | $1.03 Billion |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $1.35 Billion | 7.34% | 0.44x | $3.30 Billion |
About Tasly Pharmaceutical Group Co Ltd
Tasly Pharmaceutical Group Co., Ltd, together with its subsidiaries, engages in the research, development, production, and sale of pharmaceuticals in China. The company offers prescription drugs covering various therapeutic areas, including cardiovascular-cerebrovascular, tumor immunity, digestion and metabolism, and neuroscience; over-the-counter drugs; modern TCM; biological drugs; and chemical… Read more